logo
Whooping cough cases approach near record numbers

Whooping cough cases approach near record numbers

Yahoo25-12-2024

COLUMBUS, Ohio (WCMH) — Holiday cheer is in the air, and so are infections. According to the Centers for Disease Control and Prevention, whooping cough cases in the United States are beginning to return to pre-pandemic levels.
Whooping cough is often referred to as pertussis. According to Nationwide Children's Hospital's Chief of Infectious Diseases, Dr. Jason Newland, there are over 32,000 recorded cases this year alone in the U.S. which is six times greater than last year.
Dr. Newland said they're also noticing a spike in cases across the state.
'In Ohio, we're double the amount of last year at 1600 cases reported,' he said.
Dr. Newland said whooping cough often presents similar symptoms as the common cold. This can include fever, runny nose, and eventually an aggressive cough.
'The difference is the cough can come in paroxysms, but the better word for it is just a lot at one time to where we hear that we say whoop because you cough, cough, cough, cough, cough and then you go whoop because you've got to breathe,' he said.
Dr. Newland said the whooping cough vaccination is the best way to prevent it starting at two months old.
'And then because the vaccine is not perfect, meaning it doesn't provide me protection the rest of my life, you really need to get it every ten years,' Dr. Newland said.
Dr. Newland said the problem they're seeing is less people are getting vaccinated.
'You and I, we get pertussis, we're going to cough, and we're going to cough a lot, and we might cough 100 days, and we might cough so much we break a rib, or we cough so much that we want to vomit, all terrible things which is why I want my vaccine,' Dr. Newland said.
According to Dr. Newland, the most susceptible group is infants.
'They can come to the hospital not breathing,' Dr. Newland said. 'They can have neurologic conditions making them seize and they can die.'
This is why as you gather for the holidays, Dr. Newland recommends taking proper precautions.
'You can always wear a mask to prevent things like pertussis, things like RSV, things like influenza,' Dr. Newland said. 'Influenza's rip roaring right now. All of these things you do and let's not forget washing our hands, you can use distance. We learned these things during the pandemic. We can keep doing that to protect us against pertussis and all of these respiratory illnesses.'
Dr. Newland said treatment is simple, but whooping cough is an airborne disease which makes it highly contagious.
'If we all get vaccinated that are going to be around the youngest and most vulnerable, we help protect them even more,' Dr. Newland said. 'So, having 30,000 cases is scary because you know there's some infants in that and you're putting others at risk.'
Whooping cough is also often referred to as the 100-day cough because it can last for weeks or months.
Copyright 2024 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hampton Roads infant with rare genetic disorder in critical need of liver donor
Hampton Roads infant with rare genetic disorder in critical need of liver donor

Yahoo

time2 hours ago

  • Yahoo

Hampton Roads infant with rare genetic disorder in critical need of liver donor

PORTSMOUTH, Va. (WAVY) – Infant Rhett Powell will celebrate his first birthday Friday, but his parents are hoping to give him something far greater than a toy; they want him to have the gift of life. Rhett was diagnosed at just two months' old with a rare genetic disorder, Alagille Syndrome. Only about 1 in every 30,000 babies are born with the condition, according to the National Institutes of Health. His mother, Jenna, never imagined Rhett would be part of that statistic. At 10 months, doctors revealed his condition was compounded with liver disease and his parents also learned he would need a liver transplant. 'There's also a lot of risk with the transplant,' she says. 'And we know that the risk of a transplant outweighs keeping his liver the way it is. So, there's a mix of emotions: sadness, happiness, excitement, nervousness, all of the above. Alagille Syndrome is known to cause narrowed and malformed bile ducts in the liver, which is one of Rhett's toughest hurdles. His condition causes jaundice, issues with his heart and eyes, and itching so severe that he scratches until he bleeds. His blood is also highly acidic. Jenna says Rhett only weighs 16 lbs. and is on a feeding tube. His father was left with no choice but to quit his job as he can't crawl or move on his own. For the past two months, Jenna has been searching high and low for a liver donor who could be her baby boy's perfect match. 'His perfect match would be someone that has B or O blood type,' she says. 'Negative or positive, it doesn't matter. There would need to be aged around, 18 to 60. Nonsmoker, someone with no major organ diseases or preexisting conditions like diabetes or high blood pressure. No major abdominal surgeries; no illicit drug use. And someone that is willing to do that.' If you think you may be a match or know of someone who could be a match, you can contact Jenna Powell at (757) 556-5182. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Hundreds of CDC workers are reinstated but majority of fired public health staffers left in limbo
Hundreds of CDC workers are reinstated but majority of fired public health staffers left in limbo

Yahoo

time3 hours ago

  • Yahoo

Hundreds of CDC workers are reinstated but majority of fired public health staffers left in limbo

Supporters of the Centers for Disease Control and Prevention demonstrate outside the center's entrance in Atlanta during a rally in April. These rallies have happened weekly since the mass layoffs first started at the CDC in February. Jill Nolin/Georgia Recorder Fired workers of the Atlanta-based Centers for Disease Control and Prevention and their supporters are pushing for more public health jobs to be restored after a portion of the center's terminated workforce was reinstated this week. Many of the more than 460 workers reinstated are assigned to the National Center for Environmental Health or the National Center for HIV, Viral Hepatitis, STD and Tuberculosis Prevention, according to the Associated Press. U.S. Health Secretary Robert F. Kennedy Jr. announced plans to slash 10,000 jobs in late March, including 2,400 jobs at the CDC. The reinstated workers received a two-paragraph memorandum Wednesday from Tom Nagy, chief human capital officer with the U.S. Department of Health and Human Services, that said they were no longer part of the previously announced reduction in force, according to a copy of the memo obtained by the Georgia Recorder. 'You will not be affected by the upcoming RIF,' the memo says. Emily G. Hilliard, press secretary for the federal agency, did not respond to specific questions about the number of jobs reinstated or which CDC programs were targeted. 'Under Secretary Kennedy's leadership, the nation's critical public health functions remain intact and effective,' Hilliard said in a statement Thursday. 'The Trump Administration is committed to protecting essential services—whether it's supporting coal miners and firefighters through NIOSH, safeguarding public health through lead prevention, or researching and tracking the most prevalent communicable diseases.' Sarah Boim, a former communication specialist at the CDC who is a leader of the group Fired But Fighting, said some of the reinstated staffers were already back at work Thursday. Boim said the restored jobs are not enough, but she said she is skeptical that more people will be brought back since the newly reinstated group represents about 20% of the job losses at the CDC – which would mirror what Kennedy said earlier would need to be reversed because of 'mistakes' made by the Department of Government Efficiency. Lawsuits challenging the terminations at the CDC and other federal agencies are also working their way through the courts. Boim said the saga has left laboratory scientists and others sidelined from their work while collecting administrative pay. 'It's mind boggling — the level of inefficiency and chaos that this whole process has sown,' she said. 'I would like people to know that their money was going to pay for people with critical jobs to not do their jobs.' Georgia Democrats who have pressed for the Trump administration to reverse course on the CDC cuts cheered the news Thursday but pressed for more fired CDC workers to be brought back. 'The rehiring of hundreds of dedicated health workers, many of whom call Georgia home, is welcome news for those of us who believe that public health is vital to our wellbeing and safety — not a political game,' U.S. Sen. Raphael Warnock said in a statement. Warnock participated in a rally outside the CDC in April. Those rallies have been held every week since the mass layoffs started in February, with one held Tuesday despite the rain after Kennedy fired members of a key vaccine panel. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

Associated Press

time3 hours ago

  • Associated Press

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease. This approval expands the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older. 'RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'We appreciate the FDA's review and thank all the participants in our clinical trial as well as the Moderna team for their dedication to protecting people against RSV.' While the risk of RSV is well recognized in infants and older adult populations, adults aged 18-59 years with chronic conditions are also vulnerable.1 Over one-third of adults aged 18-59 years have at least one underlying condition that puts them at increased risk of severe RSV disease,2 with disease burden and hospitalization rates in this population being comparable, or even exceeding, that observed in older adults.3 This approval was supported by results from Moderna's Phase 3 study ( NCT06067230 ), which evaluated the safety and immunogenicity of mRESVIA in adults aged 18-59 with underlying health conditions. The immune responses against both RSV-A and RSV-B met prespecified non-inferiority immunobridging criteria when compared to those observed in adults aged 60 years and older in the pivotal Phase 3, placebo-controlled safety and efficacy study. Comparable levels of neutralizing antibodies were observed across both the 18-49 and 50-59 age subgroups, supporting the vaccine's consistent immunogenicity profile in this at-risk, younger adult population. These findings were presented at the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) meeting in April 2025 and have been published in Clinical Infectious Diseases. The vaccine was generally well-tolerated, and the most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia and arthralgia. Moderna intends to have mRESVIA available for both younger adults at increased risk (ages 18-59) and older adults (ages 60+) in the U.S. for the 2025-2026 respiratory virus season. About mRESVIA® (Respiratory Syncytial Virus Vaccine) mRESVIA® is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells. The prefusion conformation of the F protein is a significant target of potent neutralizing antibodies and is highly conserved across both RSV-A and RSV-B subtypes. The vaccine uses the same lipid nanoparticles (LNPs) as the Moderna COVID-19 vaccines. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. mRESVIA® is a registered trademark of Moderna. INDICATION mRESVIA is a vaccine to protect you against lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV). mRESVIA is for people 60 years of age and older and also for people 18 through 59 years of age who are at increased risk for RSV (people with medical conditions such as diabetes or with diseases affecting the lungs and heart). Vaccination with mRESVIA may not protect all people who receive the vaccine. mRESVIA does not contain RSV. mRESVIA cannot give you lower respiratory tract disease caused by RSV. IMPORTANT SAFETY INFORMATION Who should not get mRESVIA? You should not get mRESVIA if you had a severe allergic reaction to any ingredient in mRESVIA. What should you tell your healthcare provider? Tell your healthcare provider about all of your medical conditions, including if you: How is mRESVIA given? mRESVIA is given as an injection into the muscle. What are the risks of mRESVIA? There is a very small chance that mRESVIA could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of mRESVIA. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. Signs of a severe allergic reaction may include: Side effects that have been reported in clinical trials with mRESVIA include: These may not be all of the possible side effects of mRESVIA. Ask your healthcare provider about any side effects that concern you. You may report side effects to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or Please click for mRESVIA Full Prescribing Information. Moderna Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the efficacy, safety and tolerability of mRESVIA; the disease burden associated with RSV, particularly in adults with certain risk factors; and the availability of mRESVIA for the 2025-2026 season. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media: Chris Ridley Head of Global Media Relations +1 617-800-3651 [email protected] Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 [email protected] 1 Prasad N, Walker TA, Waite B, et al. Respiratory syncytial virus-associated hospitalizations among adults with chronic medical conditions. Clin Infect Dis 2021; 73(1): e158-e63. 2 Wilker E, Jiang M, Francis B, et al. Burden of chronic medical conditions that are risk factors for severe RSV among adults aged 18-59 years in the United States. Poster presented at: ESCMID; April 2025; Vienna, Austria. 3 Weycker D, Averin A, Houde L, et al. Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile. Infect Dis Ther 2024; 13(1): 207-20. SOURCE: Moderna, Inc. press release

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store